Wood­cock de­fends Bio­gen's new Alzheimer's drug, says it has more sup­port­ive da­ta than many past ac­cel­er­at­ed ap­provals

Act­ing FDA com­mis­sion­er Janet Wood­cock pub­licly de­fend­ed Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm on Tues­day, say­ing it’s “a very sol­id” ac­cel­er­at­ed ap­proval, and “has a lot …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER